Cobepa completes strategic investment in BioAgilytix
Durham, NC; New York, NY; Brussels, Belgium - BioAgilytix, a leading provider of large molecule bioanalytical testing services, announced today that it has received a strategic investment from Cobepa S.A.
Founded in 2008, BioAgilytix provides large molecule bioanalysis services to pharmaceutical and biotech sponsors. With laboratory locations in North Carolina's Research Triangle area and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development of biologics across a number of industries and disease states. Cobepa is a private investment company with offices in New York and Brussels.
"We have built a team with an excellent reputation for quality science and superior service, which has allowed us to expand our work with existing customers and significantly grow our client base over the past several years," said Jim Datin, President and CEO of BioAgilytix. "Going forward, Cobepa is positioned to provide additional capital as well as access to their broad international network, which will empower us to continue serving our clients' evolving and expanding bioanalytical needs. It will enable us to invest in further building out our talented team, expanding our advanced lab facilities in both the US and Europe, and adding adjacent bioanalytical services that will benefit our customers."
"Several years ago, we identified BioAgilytix as a leader in the specialty area of large molecule bioanalysis. We are very pleased to partner with their team and support the next phase of the company's development and their objective of bringing more large molecule drugs to market, faster," said Peter Connolly, Managing Director, Cobepa North America. "Our support will provide the resources necessary to extend the company's impressive track record, retain and add to its respected team, and solidify its position as the premier worldwide provider of large molecule bioanalytical testing services."
Jean-Marie Laurent Josi, CEO of Cobepa, added: "We are very pleased to complete Cobepa's third investment in a US-based company since launching our direct US investment strategy several years ago. We look forward to a lasting and deep partnership with BioAgilytix's management team and its outstanding scientific and technical team. We share their commitment to providing innovative services around the world."
Golub Capital, a private debt platform with over $25 billion of capital under management, led a one-stop debt facility as part of the transaction.
Cobepa North America team members Peter Connolly, Andrew Hollod and Peter Batesko have joined BioAgilytix's Board of Directors.